Your browser doesn't support javascript.
loading
Virus-like Particles Identify an HIV V1V2 Apex-Binding Neutralizing Antibody that Lacks a Protruding Loop.
Cale, Evan M; Gorman, Jason; Radakovich, Nathan A; Crooks, Ema T; Osawa, Keiko; Tong, Tommy; Li, Jiaqi; Nagarajan, Raju; Ozorowski, Gabriel; Ambrozak, David R; Asokan, Mangai; Bailer, Robert T; Bennici, Anthony K; Chen, Xuejun; Doria-Rose, Nicole A; Druz, Aliaksandr; Feng, Yu; Joyce, M Gordon; Louder, Mark K; O'Dell, Sijy; Oliver, Courtney; Pancera, Marie; Connors, Mark; Hope, Thomas J; Kepler, Thomas B; Wyatt, Richard T; Ward, Andrew B; Georgiev, Ivelin S; Kwong, Peter D; Mascola, John R; Binley, James M.
Affiliation
  • Cale EM; Vaccine Research Center, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD 20892, USA.
  • Gorman J; Vaccine Research Center, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD 20892, USA.
  • Radakovich NA; Vaccine Research Center, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD 20892, USA.
  • Crooks ET; San Diego Biomedical Research Institute, San Diego, CA 92121, USA.
  • Osawa K; San Diego Biomedical Research Institute, San Diego, CA 92121, USA.
  • Tong T; Sunway University, School of Science and Technology, Department of Biological Sciences, Jalan Universiti, Bandar Sunway, 47500 Selangor Darul Ehsan, Malaysia.
  • Li J; Vaccine Research Center, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD 20892, USA.
  • Nagarajan R; Vanderbilt Vaccine Center, Vanderbilt University Medical Center, Nashville, TN 37232, USA.
  • Ozorowski G; Department of Integrative Structural and Computational Biology, The Scripps Research Institute, La Jolla, CA 92037, USA.
  • Ambrozak DR; Vaccine Research Center, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD 20892, USA.
  • Asokan M; Vaccine Research Center, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD 20892, USA.
  • Bailer RT; Vaccine Research Center, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD 20892, USA.
  • Bennici AK; Vaccine Research Center, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD 20892, USA.
  • Chen X; Vaccine Research Center, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD 20892, USA.
  • Doria-Rose NA; Vaccine Research Center, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD 20892, USA.
  • Druz A; Vaccine Research Center, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD 20892, USA.
  • Feng Y; Department of Immunology and Microbial Science, The Scripps Research Institute, La Jolla, CA 92037, USA.
  • Joyce MG; Vaccine Research Center, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD 20892, USA.
  • Louder MK; Vaccine Research Center, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD 20892, USA.
  • O'Dell S; Vaccine Research Center, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD 20892, USA.
  • Oliver C; Vaccine Research Center, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD 20892, USA.
  • Pancera M; Vaccine Research Center, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD 20892, USA.
  • Connors M; HIV-Specific Immunity Section, Laboratory of Immunoregulation, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD 20892, USA.
  • Hope TJ; Department of Cell and Molecular Biology, Feinberg Medical School, Northwestern University, Chicago, IL 60611, USA.
  • Kepler TB; Boston University Department of Microbiology, Boston, MA 02118, USA.
  • Wyatt RT; Department of Immunology and Microbial Science, The Scripps Research Institute, La Jolla, CA 92037, USA.
  • Ward AB; Department of Integrative Structural and Computational Biology, The Scripps Research Institute, La Jolla, CA 92037, USA.
  • Georgiev IS; Vanderbilt Vaccine Center, Vanderbilt University Medical Center, Nashville, TN 37232, USA; Department of Pathology, Microbiology, and Immunology, Vanderbilt University Medical Center, Nashville, TN 37232, USA.
  • Kwong PD; Vaccine Research Center, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD 20892, USA. Electronic address: pdkwong@nih.gov.
  • Mascola JR; Vaccine Research Center, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD 20892, USA. Electronic address: jmascola@nih.gov.
  • Binley JM; San Diego Biomedical Research Institute, San Diego, CA 92121, USA. Electronic address: jbinley@sdbri.org.
Immunity ; 46(5): 777-791.e10, 2017 05 16.
Article in En | MEDLINE | ID: mdl-28514685
ABSTRACT
Most HIV-1-specific neutralizing antibodies isolated to date exhibit unusual characteristics that complicate their elicitation. Neutralizing antibodies that target the V1V2 apex of the HIV-1 envelope (Env) trimer feature unusually long protruding loops, which enable them to penetrate the HIV-1 glycan shield. As antibodies with loops of requisite length are created through uncommon recombination events, an alternative mode of apex binding has been sought. Here, we isolated a lineage of Env apex-directed neutralizing antibodies, N90-VRC38.01-11, by using virus-like particles and conformationally stabilized Env trimers as B cell probes. A crystal structure of N90-VRC38.01 with a scaffolded V1V2 revealed a binding mode involving side-chain-to-side-chain interactions that reduced the distance the antibody loop must traverse the glycan shield, thereby facilitating V1V2 binding via a non-protruding loop. The N90-VRC38 lineage thus identifies a solution for V1V2-apex binding that provides a more conventional B cell pathway for vaccine design.
Subject(s)
Key words

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Peptide Fragments / Protein Conformation / HIV Antibodies / HIV Envelope Protein gp120 / HIV Infections / HIV-1 / Env Gene Products, Human Immunodeficiency Virus / Antibodies, Neutralizing Type of study: Prognostic_studies Limits: Humans Language: En Journal: Immunity Journal subject: ALERGIA E IMUNOLOGIA Year: 2017 Type: Article Affiliation country: United States

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Peptide Fragments / Protein Conformation / HIV Antibodies / HIV Envelope Protein gp120 / HIV Infections / HIV-1 / Env Gene Products, Human Immunodeficiency Virus / Antibodies, Neutralizing Type of study: Prognostic_studies Limits: Humans Language: En Journal: Immunity Journal subject: ALERGIA E IMUNOLOGIA Year: 2017 Type: Article Affiliation country: United States